MIAMI, Sept. 13 – Incyte Genomics (Nasdaq: INCY) said Wednesday it planned to create a new revenue stream by offering exclusive licenses to pharmaceutical companies for its “deep SNP” genotyping data, which will link single-nucleotide differences to specific diseases.

“Deep SNPs would be a different business model,” Incyte CEO Roy Whitfield told GenomeWeb. “It will be on an exclusive basis with high royalties.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.